Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus

por Riggs, Jeffrey M, Hanna, Richard N, Rajan, Bhargavi, Zerrouki, Kamelia, Karnell, Jodi L, Sagar, Divya, Vainshtein, Inna, Farmer, Erika, Rosenthal, Kimberly, Morehouse, Chris, de los Reyes, Melissa, Schifferli, Kevin, Liang, Meina, Sanjuan, Miguel A, Sims, Gary P, Kolbeck, Roland
Publicado 2018

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

por Sale, Matthew J., Minihane, Emma, Monks, Noel R., Gilley, Rebecca, Richards, Frances M., Schifferli, Kevin P., Andersen, Courtney L., Davies, Emma J., Vicente, Mario Aladren, Ozono, Eiko, Markovets, Aleksandra, Dry, Jonathan R., Drew, Lisa, Flemington, Vikki, Proia, Theresa, Jodrell, Duncan I., Smith, Paul D., Cook, Simon J.
Publicado 2019